

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**Charmacy Pharmaceutical Co., Ltd.**

**創美藥業股份有限公司**

*(A joint stock limited liability company established in the People's Republic of China)*

**(Stock Code: 2289)**

## **RESTORATION OF PUBLIC FLOAT**

References are made to the announcement of the Company dated 31 August 2023 in respect of the update on restoration of public float (the “**Announcement**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company was informed by the Offeror that on 4 September 2023, the Offeror has completed the Disposal by disposing of an aggregate of 3,656,500 Shares, representing approximately 3.38% of the total number of the issued share capital of the Company, to the Purchaser. To the best knowledge and belief of the Company having made all reasonable enquiries, neither the Purchaser nor its ultimate beneficial owner is a core connected person (as defined under the Listing Rules) of the Company, and they are members of the public within the meaning of Rule 8.24 of the Listing Rules.

Immediately after the completion of the Disposal, a total of 27,000,000 Shares, representing approximately 25.00% of the total number of issued share capital of the Company as at the date of this announcement, are held by the public. Accordingly, the minimum public float of the Company as required under Rules 8.08(1)(a) and 13.32(1) of the Listing Rules has been restored.

The table below sets out the shareholding structure of the Company (i) immediately before the completion of the Disposal; and (ii) immediately after the completion of the Disposal and as at the date of this announcement:

	<b>Immediately before the completion of the Disposal</b>		<b>Immediately after the completion of the Disposal and as at the date of this announcement</b>	
	<i>No. of Shares</i>	<i>Approximate % of issued Shares</i>	<i>No. of Shares</i>	<i>Approximate % of issued Shares</i>
<b>The Offeror's Concert Group (including the Transferor)</b>				
Jiangyao Group and the Offeror	50,126,500	46.41 <sup>(Note)</sup>	46,470,000	43.03 <sup>(Note)</sup>
The Transferor	34,530,000	31.97	34,530,000	31.97
<b>The Offeror's Concert Group (including the Transferor)</b>	<b>84,656,500</b>	<b>78.38</b>	<b>81,000,000</b>	<b>75.00</b>
<b>Other Shareholders</b>	<b>23,343,500</b>	<b>21.62</b>	<b>27,000,000</b>	<b>25.00</b>
<b>Total</b>	<b>108,000,000</b>	<b>100.00</b>	<b>108,000,000</b>	<b>100.00</b>

*Note:* Jiangyao Group has security interest over 5,000,000 shares, representing approximately 4.63% of the entire issued share capital of the Company, which was pledged by the Transferor in favour of Jiangyao Group. Accordingly, Jiangyao Group and the Offeror were interested in approximately 51.04% and 47.66% of the entire issued share capital of the Company, respectively, immediately before and after the completion of the Disposal.

By Order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yan Jingbin**  
*Chairman*

Shantou, the PRC, 4 September 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive directors of the Company are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Li Hanguo and Mr. Guan Jian (also known as Guan Suzhe).*